Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial

Area of Science:

• Rheumatology
• Immunology
• Clinical Trials

Background:

• Giant cell arteritis (GCA) is a serious condition affecting large arteries, primarily in older adults.
• Current treatments often involve long-term glucocorticoids, leading to significant side effects.
• Identifying distinct patient populations within GCA trials is crucial for understanding treatment efficacy.

Purpose of the Study:

• To detail the entry criteria for patients with newly diagnosed and relapsing GCA in the GiACTA trial.
• To describe the clinical characteristics and baseline features of these GCA patient subsets.
• To inform the development of targeted therapies for GCA.

Main Methods:

• Patients were categorized as newly diagnosed (≤6 weeks) or relapsing GCA (>6 weeks with high-dose prednisone).
• All patients exhibited active GCA within 6 weeks of enrollment.
• Clinical features, demographics, and comorbidities were assessed at baseline.

Main Results:

• The study included 251 patients, with 47% newly diagnosed and 53% relapsing.
• Relapsing GCA patients were heavier, had higher BMIs, and presented with more depression and osteopenia/osteoporosis.
• Common symptoms included new-onset headaches (67%) and jaw claudication (34%); 37% were diagnosed via imaging.

Conclusions:

• The GiACTA trial population reflects the epidemiology of GCA.
• Relapsing GCA patients exhibited a higher burden of comorbidities, underscoring the need for novel therapeutic strategies.
• Large-vessel imaging played a significant role in patient enrollment for this trial.